[Introduction].
Departamento de Medicina, Facultad de Medicina, Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen de Valme, Sevilla, España; European Association for the Study of Diabetes, American Diabetes Association, Sociedad Española de Endocrinología y Nutrición, Sociedad Española de Diabetes, Sociedad Andaluza de Endocrinología y Nutrición, Sociedad Española para el Estudio de la Obesidad. Electronic address: sduran@duransanz.com.
Santiago Durán
SD
García
D001559:Benzhydryl Compounds / Q000627:therapeutic use; D001693:Biological Transport, Active / Q000187:drug effects; D000068896:Canagliflozin; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D005947:Glucose / Q000378:metabolism; D005960:Glucosides / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007687:Kidney Tubules, Proximal / Q000378:metabolism; D051269:Sodium-Glucose Transporter 1 / Q000502:physiology; D051297:Sodium-Glucose Transporter 2 / Q000502:physiology; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013876:Thiophenes / Q000627:therapeutic use
D001559:Benzhydryl Compounds; D005960:Glucosides; D007004:Hypoglycemic Agents; C495674:SLC5A1 protein, human; C089180:SLC5A2 protein, human; D051269:Sodium-Glucose Transporter 1; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013876:Thiophenes; D000068896:Canagliflozin; C529054:dapagliflozin; C570240:empagliflozin; D005947:Glucose